‘2019 한국형 조현병 약물치료 지침서’에 따른 조현병에서 동반증상 및 부작용의 치료

키워드

참고문헌 (146)

1. 안용민, "주요 정신질환의 약물치료에 대한 한국형 알고리듬 개발 (1) - 알고리듬과 임상지침서의 장·단점 및 개발과 관련된 일반사항 -", 대한정신약물학회지, 13(1), pp.18~29 (2002), 대한정신약물학회
2. 김대진, "주요 정신질환의 약물치료에 대한 한국형 알고리듬 개발 (2)- 한국형 알고리듬 개발 사업내용과 기본계획, 조직구성, 알고리듬 개발의 기본원칙, 개발방법, 제한점 및 사용 시 주의점 -", 대한정신약물학회지, 13(1), pp.30~36 (2002), 대한정신약물학회
3. 배승오, "한국형 정신분열병 약물치료 알고리듬의 임상 적용 가능성 (I): 치료효과 측면에서의 분석", 대한정신약물학회지, 17(1), pp.24~34 (2006), 대한정신약물학회
4. 안용민, "한국형 정신분열병 약물치료 알고리듬의 임상 적용 가능성(II): 적용상의 문제점 및 향후 개정 방향", 대한정신약물학회지, 17(1), pp.35~49 (2006), 대한정신약물학회
5. 김승현, "한국형 정신분열병 약물치료 알고리듬의 임상 적용 가능성(III)：정신분열병 약물치료에 대한 한국형 알고리듬의 적용에 치료환경이 미치는 영향", 대한정신약물학회지, 17(2), pp.149~161 (2006), 대한정신약물학회
6. Manschreck TC, "The CATIE schizophrenia trial: results, impact, controversy", Harv Rev Psychiatry, 15, pp.245~258 (2007)
7. Swartz MS, "What CATIE found: results from the schizophrenia trial", Psychiatr Serv, 59, pp.500~506 (2008)
8. Naber D, "The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians", CNS Drugs, 23, pp.649~659 (2009)
9. Fleischhacker WW, "The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial", Schizophr Res, 78, pp.147~156 (2005)
10. Kahn RS, "Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial", Lancet, 371, pp.1085~1097 (2008)
11. Pijnenborg GH, "Differential effects of antipsychotic drugs on insight in first episode schizophrenia: data from the European First-Episode Schizophrenia Trial (EUFEST)", Eur Neuropsychopharmacol, 25, pp.808~816 (2015)
12. Citrome L, "Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications", Expert Rev Neurother, 17, pp.1029~1043 (2017)
13. Correll CU, "The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence", J Clin Psychiatry, 77, pp.1~24 (2016)
14. Miyamoto S, "The use of long-acting injectable antipsychotics in schizophrenia", Curr Treat Options Psychiatry, 4, pp.117~126 (2017)
15. Taipale H, "Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia-a nationwide study with 20-year follow-up", Schizophr Bull, 44, pp.1381~1387 (2018)
16. Moore TA, "The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update", J Clin Psychiatry, 68, pp.1751~1762 (2007)
17. Buchanan RW, "The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements", Schizophr Bull, 36, pp.71~93 (2010)
18. National Collaborating Centre for Mental Health, "National Institute for Health and Clinical Excellence: Guidance. Psychosis and Schizophrenia in Adults: Treatment and Management: Updated Edition 2014", National Institute for Health and Care Excellence, ~ (2014)
19. Barnes TR., "Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology", J Psychopharmacol, 25, pp.567~620 (2011)
20. Hasan A, "World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance", World J Biol Psychiatry, 13, pp.318~378 (2012)
21. Hasan A, "World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects", World J Biol Psychiatry, 14, pp.2~44 (2013)
22. Galletly C, "Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders", Aust N Z J Psychiatry, 50, pp.410~472 (2016)
23. Amodeo G, "Older and newer strategies for the pharmacological management of agitation in patients with bipolar disorder or schizophrenia", CNS Neurol Disord Drug Targets, 16, pp.885~890 (2017)
24. Ostinelli EG, "Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)", Cochrane Database Syst Rev, 4, pp.Cd009412~ (2018)
25. Ostinelli EG, "Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation)", Cochrane Database Syst Rev, 7, pp.Cd009377~ (2017)
26. Upthegrove R, "Depression and schizophrenia:cause, consequence, or trans-diagnostic Issue?", Schizophr Bull, 43, pp.240~244 (2017)
27. Helfer B, "Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis", Am J Psychiatry, 173, pp.876~886 (2016)
28. Galletly C, "Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders", Aust N Z J Psychiatry, 50, pp.410~472 (2016)
29. Kasper S, "Treatment of depressive symptoms in patients with schizophrenia: a randomized, open-label, parallel-group, flexible-dose subgroup analysis of patients treated with extended-release quetiapine fumarate or risperidone", Int Clin Psychopharmacol, 30, pp.14~22 (2015)
30. Lamy FX, "The use of adjunctive antipsychotics to treat depression in UK primary care", Curr Med Res Opin, 33, pp.891~898 (2017)
31. Bosanac P, "Schizophrenia and depression", Med J Aust, 199, pp.S36~S39 (2013)
32. Altshuler LL, "The expert consensus guideline series. Treatment of depression in women", Postgrad Med, pp.1~107 (2001)
33. Alexopoulos GS, "The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients", Postgrad Med, pp.1~86 (2001)
34. Naslund J, "Incidence of early anxiety aggravation in trials of selective serotonin reuptake inhibitors in depression", Acta Psychiatr Scand, 136, pp.343~351 (2017)
35. Malki K, "Highly polygenic architecture of antidepressant treatment response: comparative analysis of SSRI and NRI treatment in an animal model of depression", Am J Med Genet B Neuropsychiatr Genet, 174, pp.235~250 (2017)
36. Vahid-Ansari F, "Overcoming resistance to selective serotonin reuptake inhibitors: targeting serotonin, serotonin-1A receptors and adult neuroplasticity", Front Neurosci, 13, pp.404~ (2019)
37. Paulzen M, "Reduced clearance of venlafaxine in a combined treatment with quetiapine", Prog Neuropsychopharmacol Biol Psychiatry, 85, pp.116~121 (2018)
38. Hendset M, "The effect of coadministration of duloxetine on steady-state serum concentration of risperidone and aripiprazole: a study based on therapeutic drug monitoring data", Ther Drug Monit, 32, pp.787~790 (2010)
39. Polcwiartek C, "The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review", Psychopharmacology (Berl), 233, pp.741~750 (2016)
40. Murray M, "Variation in the response of clozapine biotransformation pathways in human hepatic microsomes to CYP1A2- and CYP3A4-selective inhibitors", Basic Clin Pharmacol Toxicol, 122, pp.388~395 (2018)
41. Williams AM, "Seizure associated with clozapine: incidence, etiology, and management", CNS Drugs, 29, pp.101~111 (2015)
42. Grover S, "Obsessive compulsive symptoms", disorder in patients with schizophrenia: prevalence, relationship with other symptom dimensions and impact on functioning, 2017, pp.250, 277~284
43. Doyle M, "Obsessive compulsive symptoms in patients with schizophrenia on clozapine and with obsessive compulsive disorder: a comparison study", Compr Psychiatry, 55, pp.130~136 (2014)
44. Szmulewicz AG, "Suicidality in clozapinetreated patients with schizophrenia: role of obsessive-compulsive symptoms", Psychiatry Res, 230, pp.50~55 (2015)
45. Wu TH, "Obsessive-compulsive symptoms in patients with schizophrenia:relationships with olanzapine pharmacological parameters, psychopathology, and quality of life", Psychiatry Res, 276, pp.1~5 (2019)
46. Fonseka TM, "Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia:a review of the experimental literature", Curr Psychiatry Rep, 16, pp.510~ (2014)
47. Schirmbeck F, "Increased orbitofrontal cortex activation associated with “pro-obsessive” antipsychotic treatment in patients with schizophrenia", J Psychiatry Neurosci, 40, pp.89~99 (2015)
48. Schirmbeck F, "Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia", Psychol Med, 41, pp.2361~2373 (2011)
49. Stryjer R, "Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study", Int Clin Psychopharmacol, 28, pp.96~98 (2013)
50. Grover S, "Obsessive-compulsive symptoms in schizophrenia: a review", Acta Neuropsychiatr, pp.1~11 (2018)
51. Eryilmaz G, "Aripirazole augmentation in clozapine-associated obsessive-compulsive symptoms in schizophrenia", Ann Gen Psychiatry, 12, pp.40~ (2013)
52. Temmingh H, "Anxiety in patients with schizophrenia:epidemiology and management", CNS Drugs, 29, pp.819~832 (2015)
53. Grillault Laroche D, "Induced obsessive compulsive symptoms (OCS) in schizophrenia patients under atypical 2 antipsychotics (AAPs): review and hypotheses", Psychiatry Res, 246, pp.119~128 (2016)
54. Schirmbeck F, "Differential effects of antipsychotic agents on obsessive-compulsive symptoms in schizophrenia: a longitudinal study", J Psychopharmacol, 27, pp.349~357 (2013)
55. Kim SW, "Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study", J Clin Psychopharmacol, 28, pp.349~352 (2008)
56. Kim SW, "The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia", Clin Neuropharmacol, 32, pp.224~226 (2009)
57. Juven-Wetzler A, "Treatment with ziprasidone for schizophrenia patients with OCD", Eur Neuropsychopharmacol, 24, pp.1454~1462 (2014)
58. Krause DL, "Ziprasidone for obsessive compulsive disorder in schizophrenia", Ther Adv Psychopharmacol, 3, pp.115~116 (2013)
59. Davis MC, "Psychopharmacology of the negative symptoms: current status and prospects for progress", Eur Neuropsychopharmacol, 24, pp.788~799 (2014)
60. Moller HJ, "Pharmacological treatment of negative symptoms in schizophrenia", Eur Arch Psychiatry Clin Neurosci, 265, pp.567~578 (2015)
61. Liang Y, "Effectiveness of amisulpride in Chinese patients with predominantly negative symptoms of schizophrenia: a subanalysis of the ESCAPE study", Neuropsychiatr Dis Treat, 13, pp.1703~1712 (2017)
62. Barnes TR, "Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness", Health Technol Assess, 21, pp.1~56 (2017)
63. Novick D, "Realworld effectiveness of antipsychotics for the treatment of negative symptoms in patients with schizophrenia with predominantly negative symptoms", Pharmacopsychiatry, 50, pp.56~63 (2017)
64. Harvey RC, "A systematic review and network meta-analysis to assess the relative efficacy of antipsychotics for the treatment of positive and negative symptoms in early-onset schizophrenia", CNS Drugs, 30, pp.27~39 (2016)
65. Zhang JP, "Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis", Int J Neuropsychopharmacol, 16, pp.1205~1218 (2013)
66. Stip E, "A neuroimaging study of emotion-cognition interaction in schizophrenia:the effect of ziprasidone treatment", Psychopharmacology (Berl), 234, pp.1045~1058 (2017)
67. Kishi T, "Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia", Int J Neuropsychopharmacol, 17, pp.343~354 (2014)
68. Bodkin JA, "Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. A pilot study examining the role of dopamine", J Nerv Ment Dis, 184, pp.295~301 (1996)
69. Wagner E, "Clozapine augmentation strategies-a systematic meta-review of available evidence. Treatment options for clozapine resistance", J Psychopharmacol, 33, pp.423~435 (2019)
70. Goff DC, "Citalopram in first episode schizophrenia: the DECIFER trial", Schizophr Res, 208, pp.331~337 (2019)
71. Lu ML, "Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-treated patients with schizophrenia: a 12-week, randomized, double-blind, placebo-controlled study", Schizophr Res, 193, pp.126~133 (2018)
72. Rahim T, "Comparison of depression symptoms between primary depression and secondary-to-schizophrenia depression", Int J Psychiatry Clin Pract, 21, pp.314~317 (2017)
73. Jakhar K, "Self-harm and suicide attempts in schizophrenia", Asian J Psychiatr, 30, pp.102~106 (2017)
74. Jones PB, "Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia:Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)", Arch Gen Psychiatry, 63, pp.1079~1087 (2006)
75. Mayerova M, "Influence of dose, gender, and cigarette smoking on clozapine plasma concentrations", Neuropsychiatr Dis Treat, 14, pp.1535~1543 (2018)
76. Bennett ME, "Treatment of substance use disorders in schizophrenia", Am J Drug Alcohol Abuse, 43, pp.377~390 (2017)
77. Petrakis IL, "Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia", Psychopharmacology (Berl), 172, pp.291~297 (2004)
78. Cather C, "Achieving smoking cessation in individuals with schizophrenia: special considerations", CNS Drugs, 31, pp.471~481 (2017)
79. Lyu X, "Naltrexone and bupropion combination treatment for smoking cessation and weight loss in patients with schizophrenia", Front Pharmacol, 9, pp.181~ (2018)
80. Brunette MF, "Benzodiazepine use and abuse among patients with severe mental illness and cooccurring substance use disorders", Psychiatr Serv, 54, pp.1395~1401 (2003)
81. Hufner K, "Neurology issues in schizophrenia", Curr Psychiatry Rep, 17, pp.32~ (2015)
82. Yuen JWY, "Clozapine-induced cardiovascular side effects and autonomic dysfunction: a systematic review", Front Neurosci, 12, pp.203~ (2018)
83. Leucht S, "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis", Lancet, 382, pp.951~962 (2013)
84. Caroff SN, "Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial", Neurol Clin, 29, pp.127~148 (2011)
85. Divac N, "Second-generation antipsychotics and extrapyramidal adverse effects", Biomed Res Int, 2014, pp.656370~ (2014)
86. Mitchell AJ, "Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis", Schizophr Bull, 39, pp.306~318 (2013)
87. Young SL, "“First do no harm.” A systematic review of the prevalence and management of antipsychotic adverse effects", J Psychopharmacol, 29, pp.353~362 (2015)
88. MacKenzie NE, "Antipsychotics, metabolic adverse effects, and cognitive function in schizophrenia", Front Psychiatry, 9, pp.622~ (2018)
89. Ward KM, "Antipsychotic-related movement disorders:drug-induced parkinsonism vs. tardive dyskinesia-key differences in pathophysiology and clinical management", Neurol Ther, 7, pp.233~248 (2018)
90. May R, "Acute laryngeal dystonia: a persisting psychiatric emergency", Australas Psychiatry, 24, pp.497~498 (2016)
91. Goga JK, "Acute laryngeal dystonia associated with aripiprazole", J Clin Psychopharmacol, 32, pp.837~839 (2012)
92. Ogino S, "Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function", Psychiatry Clin Neurosci, 68, pp.37~49 (2014)
93. Bogers J, "Dose reduction of high-dose first-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: a 1-year double-blind randomized clinical trial", Eur Neuropsychopharmacol, 28, pp.1024~1034 (2018)
94. Loonen A, "The mechanism of drug-induced akathisia", CNS Spectr, 15, pp.491~494 (2011)
95. Salem H, "Revisiting antipsychotic-induced akathisia: current issues and prospective challenges", Curr Neuropharmacol, 15, pp.789~798 (2017)
96. Juncal-Ruiz M, "Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment", Psychopharmacology (Berl), 234, pp.2563~2570 (2017)
97. Grattan DR, "60 years of neuroendocrinology: the hypothalamoprolactin axis", J Endocrinol, 226, pp.T101~T122 (2015)
98. Capozzi A, "Hyperprolactinemia:pathophysiology and therapeutic approach", Gynecol Endocrinol, 31, pp.506~510 (2015)
99. Montejo AL, "Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia", Rev Psiquiatr Salud Ment, 9, pp.158~173 (2016)
100. De Hert M, "Relationship between antipsychotic medication, serum prolactin levels and osteoporosis", osteoporotic fractures in patients with schizophrenia: a critical literature review, 2016, pp.15, 809~823
101. Chen JX, "Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: a randomized, double-blind, placebo-controlled, dose-response study", Psychoneuroendocrinology, 58, pp.130~140 (2015)
102. Montejo AL, "Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics", Front Neuroendocrinol, 45, pp.25~34 (2017)
103. Yoon HW, "Comparing the effectiveness and safety of the addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia:a multicenter, open-label, prospective study", Clin Neuropharmacol, 39, pp.288~294 (2016)
104. Krysiak R, "The effect of bromocriptine treatment on sexual functioning and depressive symptoms in women with mild hyperprolactinemia", Pharmacol Rep, 70, pp.227~232 (2018)
105. Belvederi Murri M, "Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis", Drugs R D, 15, pp.45~62 (2015)
106. Berman BD, "Neuroleptic malignant syndrome: a review for neurohospitalists", Neurohospitalist, 1, pp.41~47 (2011)
107. Ware MR, "Neuroleptic malignant syndrome:diagnosis and management", Prim Care Companion CNS Disord, 20 (2018)
108. Oruch R, "Neuroleptic malignant syndrome: an easily overlooked neurologic emergency", Neuropsychiatr Dis Treat, 13, pp.161~175 (2017)
109. Velamoor R, "Neuroleptic malignant syndrome: a neuro-psychiatric emergency: recognition, prevention, and management", Asian J Psychiatr, 29, pp.106~109 (2017)
110. Pileggi DJ, "Neuroleptic malignant syndrome", Ann Pharmacother, 50, pp.973~981 (2016)
111. Macaluso M, "Tardive dyskinesia: a historical perspective", J Psychiatr Pract, 23, pp.121~129 (2017)
112. Correll CU, "Epidemiology, prevention, and assessment of tardive dyskinesia and advances in treatment", J Clin Psychiatry, 78, pp.1136~1147 (2017)
113. Mentzel TQ, "Clozapine monotherapy as a treatment for antipsychotic-induced tardive dyskinesia: a meta-analysis", J Clin Psychiatry, 79 (2018)
114. Aguilar L, "Tardive dyskinesia after aripiprazole treatment that improved with tetrabenazine, clozapine, and botulinum toxin", Front Pharmacol, 10, pp.281~ (2019)
115. Hauser RA, "KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia", Am J Psychiatry, 174, pp.476~484 (2017)
116. Fernandez HH, "Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study", Neurology, 88, pp.2003~2010 (2017)
117. Soares-Weiser K, "Vitamin E for antipsychotic-induced tardive dyskinesia", Cochrane Database Syst Rev, 1, pp.Cd000209~ (2018)
118. Manu P, "Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management", Acta Psychiatr Scand, 132, pp.97~108 (2015)
119. Gao K, "Subjective versus objective weight gain during acute treatment with second-generation antipsychotics in schizophrenia and bipolar disorder", J Clin Psychopharmacol, 36, pp.637~642 (2016)
120. Magni LR, "Superwellness Program: a cognitive-behavioral therapy-based group intervention to reduce weight gain in patients treated with antipsychotic drugs", Braz J Psychiatry, 39, pp.244~251 (2017)
121. Ribeiro ELA, "Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews", Eur J Clin Pharmacol, 74, pp.1215~1233 (2018)
122. Lau SL, "Predicting weight gain in patients treated with clozapine: the role of sex, body mass index, and smoking", J Clin Psychopharmacol, 36, pp.120~124 (2016)
123. Gressier F, "Pharmacogenetics of clozapine response and induced weight gain: a comprehensive review and meta-analysis", Eur Neuropsychopharmacol, 26, pp.163~185 (2016)
124. Lord CC, "The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C", J Clin Invest, 127, pp.3402~3406 (2017)
125. Zhuo C, "Topiramate and metformin are effective add-on treatments in controlling antipsychotic-induced weight gain: a systematic review and network meta-analysis", Front Pharmacol, 9, pp.1393~ (2018)
126. Zheng W, "Amantadine for antipsychotic-related weight gain: meta-analysis of randomized placebo-controlled trials", J Clin Psychopharmacol, 37, pp.341~346 (2017)
127. Hoffmann VP, "Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study", J Clin Psychiatry, 73, pp.216~223 (2012)
128. Hoffman RP, "The complex inter-relationship between diabetes and schizophrenia", Curr Diabetes Rev, 13, pp.528~532 (2017)
129. Mamakou V, "Schizophrenia and type 2 diabetes mellitus", Psychiatriki, 29, pp.64~73 (2018)
130. Agarwal SM, "Brain insulin action in schizophrenia: something borrowed and something new", Neuropharmacology, pp.107633~ (2019)
131. Agarwal SM, "Brain insulin action: implications for the treatment of schizophrenia", Neuropharmacology (2019)
132. Marder SR, "Physical health monitoring of patients with schizophrenia", Am J Psychiatry, 161, pp.1334~1349 (2004)
133. Larsen JR, "Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial", JAMA Psychiatry, 74, pp.719~728 (2017)
134. Guina J, "Oral glucose tolerance test performance in olanzapine-treated schizophreniaspectrum patients is predicted by BMI and triglycerides but not olanzapine dose or duration", Hum Psychopharmacol, 32 (2017)
135. Takeuchi Y, "Atypical antipsychotics and the risk of hyperlipidemia: a sequence symmetry analysis", Drug Saf, 38, pp.641~650 (2015)
136. Himmerich H, "Weight gain and metabolic changes during treatment with antipsychotics and antidepressants", Endocr Metab Immune Disord Drug Targets, 15, pp.252~260 (2015)
137. Coughlin M, "Enhancing metabolic monitoring for children and adolescents using second-generation antipsychotics", Int J Ment Health Nurs, 27, pp.1188~1198 (2018)
138. Woo YS, "Effects of switching to aripiprazole from current atypical antipsychotics on subsyndromal symptoms and tolerability in patients with bipolar disorder", Int Clin Psychopharmacol, 31, pp.275~286 (2016)
139. Mandrioli R, "Evaluation of the pharmacokinetics, safety and clinical efficacy of ziprasidone for the treatment of schizophrenia and bipolar disorder", Expert Opin Drug Metab Toxicol, 11, pp.149~174 (2015)
140. Nilsson BM, "Tachycardia in patients treated with clozapine versus antipsychotic long-acting injections", Int Clin Psychopharmacol, 32, pp.219~224 (2017)
141. Czekalla J, "Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics", J Clin Psychiatry, 62(Suppl 2), pp.35~40 (2001)
142. Beach SR, "QTc prolongation, torsades de pointes, and psychotropic medications", Psychosomatics, 54, pp.1~13 (2013)
143. Hasnain M, "QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review", CNS Drugs, 28, pp.887~920 (2014)
144. Takeuchi H, "Antipsychotic polypharmacy and corrected QT interval: a systematic review", Can J Psychiatry, 60, pp.215~222 (2015)
145. Polcwiartek C, "The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach", Psychopharmacology (Berl), 232, pp.3297~3308 (2015)
146. Hwang TJ, "Fast versus slow strategy of switching patients with schizophrenia to aripiprazole from other antipsychotics", J Clin Psychopharmacol, 35, pp.635~644 (2015)

관련 논문AI추천